Lonza shows improvement at low end of forecast

- Last updated on GMT

Related tags: United states dollar, Lonza

Lonza, the maker of L-carnitine and B vitamins, said today that
profits for 2004 climbed by more than half, coming in at the low
end of analysts' forecasts.

The Swiss speciality chemicals group reported operating profits of SF212 million (€136.9m) and net income of SF138 million, a 52 per cent rise on the prior year.

The company blamed weak niacin prices, as well as the US dollar exchange rate and the postponement of biopharmaceutical deliveries until this year, on its failure to match earnings targets set at the beginning of the year.

In its organic and fine chemicals unit, the market is expected to remain competitive for a number of product lines, but the group said it will focus on niche markets in nutrition and cosmetics to support long-term profitability.

"The board of directors expects sales growth and a solid improvement in earnings in 2005 in line with our short-term, two-year operating income targets of between SF300 million and SF400 million,"​ Lonza said in a statement.

The company ruled out a restructuring of operations, something that had been widely expected in the market.

Analyst Bernd Pomrehn at Bank Sarasin told an agency report that "people were hoping they would make a move to sell their polymer intermediates but there is no sign of that"​.

Related topics: Suppliers, Vitamins & premixes

Related news

Show more

Related products

show more

Vitamins & Minerals as Nature intended

Vitamins & Minerals as Nature intended

LEHVOSS Nutrition | 12-Dec-2019 | Data Sheet

LEHVOSS Nutrition offer a range of natural, organic certified, vegan and active vitamins and minerals. These are offered as “whole-food complexes” in their...

20 Years Palm Tocotrienols Brain Health Research

20 Years Palm Tocotrienols Brain Health Research

ExcelVite Sdn. Bhd. | 25-Sep-2019 | Technical / White Paper

Research of Vitamin E tocotrienol in brain health and neuroprotection began twenty years ago.
Today, other health benefits have been discovered...

MenaQ7® Partners Benefit From K2 Outreach

MenaQ7® Partners Benefit From K2 Outreach

NattoPharma USA, Inc. | 22-Apr-2019 | Case Study

MenaQ7® K2 as MK-7 provides health benefits for all ages. That is a fact clinically proven by NattoPharma and communicated to practitioners and consumers...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars